276 related articles for article (PubMed ID: 37193819)
1. Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implications.
Wang Y; Chen H
Oncogene; 2023 Jun; 42(24):1970-1979. PubMed ID: 37193819
[TBL] [Abstract][Full Text] [Related]
2. Glycosylation-related Diagnostic and Therapeutic Drug Target Markers in Hepatocellular Carcinoma.
Watson ME; Diepeveen LA; Stubbs KA; Yeoh GC
J Gastrointestin Liver Dis; 2015 Sep; 24(3):349-57. PubMed ID: 26405707
[TBL] [Abstract][Full Text] [Related]
3. Glycoproteomic contributions to hepatocellular carcinoma research: a 2023 update.
Zheng Y; Gao K; Gao Q; Zhang S
Expert Rev Proteomics; 2023; 20(10):211-220. PubMed ID: 37882248
[TBL] [Abstract][Full Text] [Related]
4. The O-GlcNAcylation and its promotion to hepatocellular carcinoma.
Zhang J; Xun M; Li C; Chen Y
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188806. PubMed ID: 36152903
[TBL] [Abstract][Full Text] [Related]
5. Histidine-rich glycoprotein function in hepatocellular carcinoma depends on its N-glycosylation status, and it regulates cell proliferation by inhibiting Erk1/2 phosphorylation.
Zhang Q; Jiang K; Li Y; Gao D; Sun L; Zhang S; Liu T; Guo K; Liu Y
Oncotarget; 2015 Oct; 6(30):30222-31. PubMed ID: 26336134
[TBL] [Abstract][Full Text] [Related]
6. ST6GAL1 inhibits metastasis of hepatocellular carcinoma via modulating sialylation of MCAM on cell surface.
Zou X; Lu J; Deng Y; Liu Q; Yan X; Cui Y; Xiao X; Fang M; Yang F; Sawaki H; Sato T; Tan B; Lu X; Feng B; Kuno A; Narimatsu H; Gao C; Zhang Y
Oncogene; 2023 Feb; 42(7):516-529. PubMed ID: 36528750
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
8. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
9. Protein glycosylation in viral hepatitis-related HCC: Characterization of heterogeneity, biological roles, and clinical implications.
Zhang S; Cao X; Gao Q; Liu Y
Cancer Lett; 2017 Oct; 406():64-70. PubMed ID: 28789967
[TBL] [Abstract][Full Text] [Related]
10. Glycosylation-related molecular subtypes and risk score of hepatocellular carcinoma: Novel insights to clinical decision-making.
Shi Y; Wang Y; Yang R; Zhang W; Zhang Y; Feng K; Lv Q; Niu K; Chen J; Li L; Zhang Y
Front Endocrinol (Lausanne); 2022; 13():1090324. PubMed ID: 36605944
[TBL] [Abstract][Full Text] [Related]
11. Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation.
Cheng H; Wang S; Gao D; Yu K; Chen H; Huang Y; Li M; Zhang J; Guo K
Cell Oncol (Dordr); 2023 Apr; 46(2):283-297. PubMed ID: 36454514
[TBL] [Abstract][Full Text] [Related]
12. miR-9 inhibits the metastatic ability of hepatocellular carcinoma via targeting beta galactoside alpha-2,6-sialyltransferase 1.
Han Y; Liu Y; Fu X; Zhang Q; Huang H; Zhang C; Li W; Zhang J
J Physiol Biochem; 2018 Aug; 74(3):491-501. PubMed ID: 30006781
[TBL] [Abstract][Full Text] [Related]
13. O-GlcNAcylation promotes the migratory ability of hepatocellular carcinoma cells via regulating FOXA2 stability and transcriptional activity.
Huang H; Wu Q; Guo X; Huang T; Xie X; Wang L; Liu Y; Shi L; Li W; Zhang J; Liu Y
J Cell Physiol; 2021 Nov; 236(11):7491-7503. PubMed ID: 33843053
[TBL] [Abstract][Full Text] [Related]
14. Functional long non-coding RNAs in hepatocellular carcinoma.
Xie C; Li SY; Fang JH; Zhu Y; Yang JE
Cancer Lett; 2021 Mar; 500():281-291. PubMed ID: 33129957
[TBL] [Abstract][Full Text] [Related]
15. Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma.
Kumar AR; Devan AR; Nair B; Nair RR; Nath LR
Curr Cancer Drug Targets; 2022; 22(9):725-740. PubMed ID: 35301949
[TBL] [Abstract][Full Text] [Related]
16. Potential Regulatory Role of Human-Carboxylesterase-1 Glycosylation in Liver Cancer Cell Growth.
Na K; Kim M; Kim CY; Lim JS; Cho JY; Shin H; Lee HJ; Kang BJ; Han DH; Kim H; Baik JH; Swiatek-de Lange M; Karl J; Paik YK
J Proteome Res; 2020 Dec; 19(12):4867-4883. PubMed ID: 33206527
[TBL] [Abstract][Full Text] [Related]
17. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
Hu M; Wang M; Lu H; Wang X; Fang X; Wang J; Ma C; Chen X; Xia H
Oncotarget; 2016 Jul; 7(28):43419-43431. PubMed ID: 27270326
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
19. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
20. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
Liu Y; Xu Q; Deng F; Zheng Z; Luo J; Wang P; Zhou J; Lu X; Zhang L; Chen Z; Zhang Q; Chen Q; Zuo D
J Exp Clin Cancer Res; 2023 Feb; 42(1):38. PubMed ID: 36721234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
